← Back to all signals
RESEARCH PAPER ANALYSIS

Stimuli-Chromic Oxazolidine Derivatives as Highly Efficient Molecular Probes for Monitoring Fibrillation Kinetics and Intracellular Detection of Amyloid Fibrils.

The authors report two membrane-permeable, aggregation-induced-emission oxazolidine probes (OX1/OX2) that turn on red fluorescence upon binding amyloid fibrils, detect intracellular α-synuclein and insulin aggregates, and — per docking—show stronger fibril binding (OX2) than ThT.

PMID42044386
JournalBiochemistry
Publication Date2026-04-27
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

The authors report two membrane-permeable, aggregation-induced-emission oxazolidine probes (OX1/OX2) that turn on red fluorescence upon binding amyloid fibrils, detect intracellular α-synuclein and insulin aggregates, and — per docking—show stronger fibril binding (OX2) than ThT.

WHY IT MATTERS

Research significance

By enabling sensitive intracellular and red-shifted detection of α-synuclein assemblies with low cytotoxicity, these probes are valuable tools for studying aggregation kinetics, cellular pathology, and for screening or validating therapeutics and biomarkers relevant to Parkinson's disease.

ABSTRACT

Source abstract

Misfolding and aggregation of proteins into amyloid fibrils is a main pathological hallmark of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. Thus, development of probes with the potential to cross biological membranes and detect intracellular aggregates is an area of intense research. In the present study, we have reported the synthesis of two new stimuli-chromic oxazolidine derivatives (OX1 and OX2), with aggregation-induced emission (AIE) characteristics, for monitoring fibrillation kinetics and intracellular detection of amyloid fibrils. Although both probes are nonfluorescent in the presence of monomers and soluble oligomers, their binding to amyloid fibrils is accompanied by considerable red fluorescence. We suggest that changes in the polarity of the amyloid fibril microenvironment, caused by structural changes and exposure of hydrophobic regions during the fibrillation process, promote the selective binding and aggregation of these compounds on the surface of amyloid fibrils, leading to their considerable fluorescence emission. Cellular experiments indicate that both dyes are membrane-permeable without any significant cytotoxicity and can detect intracellular fibrils of α-synuclein and human insulin. Molecular docking studies suggest stronger binding affinity of OX2 than that of ThT for monomers and amyloid fibrils. In summary, we believe that properties such as intracellular detection of amyloid fibrils, red fluorescence without any significant interference with autofluorescence, and solid-state solvatochromic and AIE characteristics may distinguish OX1/OX2 from ThT and previously reported probes, making these compounds more suitable candidates for the detection of amyloid aggregates both in vitro and in vivo.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic